All News
Filter News
Found 809,020 articles
-
According to a BIO report, less than a third of executive team members are women. BioSpace spoke with three influential women in biopharma to get their advice on breaking the executive barrier.
-
HIROTSU BIO SCIENCE INC.: World's First Test for Early-Stage Pancreatic Cancer, "N-NOSE® plus Pancreas", Now Available
11/17/2022
HIROTSU BIO SCIENCE INC. is pleased to announce the commercialization of "N-NOSE plus Pancreas," the first next-generation "cancer type specific test" for the "N-NOSE®".
-
RespireRx Pharmaceuticals Inc. Announces Entry into Letter of Intent with Australian Headquartered CRO for Dronabinol Development for Obstructive Sleep Apnea
11/17/2022
RespireRx Pharmaceuticals Inc. is pleased to announce that, on November 14, 2022, the Company entered into a letter of intent with an Australia headquartered bespoke clinical research organization focused on cannabinoid and psychedelic clinical research.
-
Fargo Center for Dermatology Is First in State to Offer Non-Surgical Technology For Treating Common Skin Cancers
11/17/2022
SkinCure Oncology, the world leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiotherapy, the most advanced non-surgical technology for the treatment of common skin cancers, announced the availability of the technology in North Dakota.
-
VYNE Therapeutics Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, for the Treatment of VitiligoTopline proof-of-concept data in vitiligo patients expected in 1H 2023
11/17/2022
VYNE Therapeutics Inc. today announced that the first subjects have been dosed in a Phase 1a/b clinical trial evaluating VYN201 for the treatment of vitiligo.
-
IMUNON Announces Strategic Investment in Transomic Technologies
11/17/2022
IMUNON, Inc. announced a $375,000 investment in Transomic Technologies, a private company offering a comprehensive array of CRISPR, RNAi and gene expression tools and services.
-
Mesa Labs Acquires Belyntic’s Peptide Purification Business
11/17/2022
Mesa Laboratories, Inc. announced the acquisition of substantially all of the assets and certain liabilities related to Belyntic GmbH’s peptide purification business.
-
NuVasive Showcases Latest Innovation in Virtual Global Event
11/17/2022
NuVasive, Inc., the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, held a virtual event yesterday showcasing the Company's latest innovation across its market-leading 360 portfolios.
-
TZIELD™ (teplizumab-mzwv) approved by FDA as the first and only treatment indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D
11/17/2022
Provention Bio, Inc. (Nasdaq: PRVB) (the "Company") today announced that the United States Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for TZIELD (teplizumab-mzwv), an anti-CD3-directed antibody, for intravenous use, as the first and only immunomodulatory treatment to delay the onset of Stage 3 T1D in adult and pediatric patients aged 8 years and older with stage 2 T1D.
-
Federal Court Rules for Masimo in Suit Against Former Engineer for Unlawful Theft of Company’s Pulse Oximeter Trade Secrets
11/17/2022
The United States District Court for the Central District of California has ruled that a former Masimo engineer misappropriated trade secrets related to Masimo’s pulse oximetry technology.
-
Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19
11/17/2022
Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced a partnership with Population Health Partners, L.P. (PHP) a global life-science firm dedicated to solving the health and economic challenges presented by prevalent diseases.
-
Rezo, Founded by Renowned UCSF Scientists, Launches with $78 Million Series A to Advance Pipeline of Precision Therapeutics Based on Groundbreaking Integrated Disease Network Mapping Platform
11/17/2022
Rezo Therapeutics, a biotechnology company pioneering the integrated mapping of disease networks for precision therapeutics, launched with $78 million from a Series A financing.
-
Palisade Bio Releases In-Depth Explanation of Scientific Approach of Lead Product Candidate LB1148 Through Animated Video
11/17/2022
Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announces the release of its new animated video for its lead asset in development, LB1148.
-
ABVC BioPharma Provides Vitargus® Update - Phase II Vitargus® Study Protocol Received Thai FDA Approval
11/17/2022
ABVC BioPharma, Inc. today announced that the Vitargus® Phase II Clinical Study Protocol has been approved by the Thailand Food and Drug Administration (FDA).
-
Jeune Aesthetics Announces Positive Durability Results for KB301 in the PEARL-1 Extension Cohort, an Investigational Gene-based Treatment for Improvement of Fine Lines and Wrinkles
11/17/2022
Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) today announced nine-month durability of effect in the extension cohort of the PEARL-1 study of KB301, an investigational gene-based treatment designed to address the underlying biology of aging skin for improvement of fine lines and wrinkles.
-
RedHill Biopharma Announces Positive New Data with Opaganib for Nuclear Radiation Injury
11/17/2022
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced positive in vivo results from a new pre-clinical study evaluating the effects of opaganib[1] on radiation-induced hematologic and renal toxicity, undertaken by RedHill and its partner Apogee Biotechnology Corporation ("Apogee").
-
Boehringer Ingelheim Welcomes New 2023 GOLD Report Positioning LAMA/LABA as the Preferred Treatment for the Majority of Patients with COPD
11/17/2022
Boehringer Ingelheim Pharmaceuticals Inc. welcomes the updated 2023 Global Initiative for Chronic Obstructive Lung Disease Report recommending long‐acting muscarinic antagonist plus long‐acting beta‐agonist as the optimal first-line treatment option for most patients with COPD, regardless of exacerbation risk.
-
Conformis Announces Full Commercial Launch of Imprint™Conformis’ Imprint™ knee system introduces the new “Made-to-Measure” product category option for Total Knee Arthroplasty (TKA)
11/17/2022
Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, today announced the full commercial launch of its new Imprint™ knee system.
-
RenovoRx Announces Presentations at the Advanced Interventional Management Symposium (AIMsymposium) Highlighting its Innovative RenovoTAMP® Therapy Platform for Targeted Treatment of Cancers
11/17/2022
RenovoRx Announces Presentations at the Advanced Interventional Management Symposium (AIMsymposium) Highlighting its Innovative RenovoTAMP ® Therapy Platform for Targeted Treatment of Cancers.
-
Research Published in Melanoma Management Finds that 99% of Patients with Uveal Melanoma Tested with DecisionDx®-UM Gain Value from the Results
11/17/2022
Castle Biosciences, Inc. (Nasdaq: CSTL) today announced the publication of a study completed in collaboration with the Melanoma Research Foundation (MRF) in which most patients diagnosed with uveal melanoma (UM) indicated their desire for prognostic testing at diagnosis, reported finding value in their test result and experienced lower decision regret, regardless of whether their test result indicated that their UM tumor was at a high or low risk of metastasis.